Palisade Bio (NASDAQ:PALI) Shares Scheduled to Reverse Split on Monday, April 8th

Shares of Palisade Bio, Inc. (NASDAQ:PALI) are set to reverse split on the morning of Monday, April 8th. The 1-15 reverse split was announced on Monday, April 8th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 8th.

Palisade Bio Stock Down 1.4 %

Shares of NASDAQ:PALI traded down $0.01 during midday trading on Thursday, reaching $0.38. The company’s stock had a trading volume of 152,423 shares, compared to its average volume of 2,530,181. The firm has a 50 day moving average of $0.44 and a 200-day moving average of $0.52. The firm has a market capitalization of $3.56 million, a P/E ratio of -0.21 and a beta of 1.33. Palisade Bio has a 12-month low of $0.36 and a 12-month high of $2.44.

Institutional Trading of Palisade Bio

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of Palisade Bio in the 4th quarter worth about $31,000. State Street Corp purchased a new stake in Palisade Bio during the 2nd quarter valued at about $38,000. Vanguard Group Inc. grew its position in Palisade Bio by 91.3% during the 3rd quarter. Vanguard Group Inc. now owns 68,054 shares of the company’s stock valued at $40,000 after purchasing an additional 32,485 shares during the last quarter. Renaissance Technologies LLC grew its position in Palisade Bio by 1,396.0% during the 3rd quarter. Renaissance Technologies LLC now owns 512,070 shares of the company’s stock valued at $51,000 after purchasing an additional 477,840 shares during the last quarter. Finally, Geode Capital Management LLC purchased a new stake in Palisade Bio during the 2nd quarter valued at about $72,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.